StemRIM Inc. (JP:4599)
:4599
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥361.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥18.99B
Enterprise Value¥14.54B
Total Cash (Recent Filing)¥6.99B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.42
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero debt materially reduces financial risk and preserves strategic optionality over the medium term. For a biotech focused on R&D, low leverage supports funding future trials or licensing deals without debt-servicing pressure, giving management time to commercialize or monetize IP.
Proprietary IP & Licensing ModelA licensing and collaboration revenue model built on proprietary stem-cell technologies is structurally advantageous: it can scale through partnerships, reduce capital intensity versus solo commercialization, and generate milestone-driven non-dilutive inflows if IP translates into partner programs.
Lean Organizational StructureA small workforce implies a relatively lean cost base and focused R&D operations, which can extend runway and allow targeted use of capital. For an early-stage biotech, disciplined headcount can preserve resources while pursuing selective partnerships or milestone-driven development.
Bears Say
Revenue DisappearanceComplete loss of reported revenue over multiple years signals high dependence on irregular or one-off income and weak commercial traction. Structurally, this undermines forecastability, makes funding cycles more frequent, and raises execution risk for sustaining development programs.
Persistent Cash BurnLarge negative operating cash flows across consecutive years indicate the business is not self-sustaining and must rely on balance sheet resources or external financing. Persistent burn increases dilution risk or forces asset-light pivots, constraining long-term R&D plans and partner negotiations.
Eroding Equity BaseDeclining equity reflects cumulative losses that shrink the capital cushion available for development and commercialization. Over time, a reduced equity base limits strategic flexibility, increases vulnerability to funding shocks, and may necessitate dilutive capital raises or curtailed programs.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥361.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥18.99B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Jun 17, 2026 which is in 80 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Mar 11, 2026. The company reported -¥6.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.42.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥6.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.333%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―